# Apatinib for Advanced Lung Squmamous Carcinoma

> **NCT03725423** · PHASE4 · UNKNOWN · sponsor: **Xuzhou Central Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Lung Squamous Cell Carcinoma

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03725423
- **Lead sponsor:** Xuzhou Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03725423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03725423, "Apatinib for Advanced Lung Squmamous Carcinoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03725423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*